0.83
+0.0378(+4.78%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.79 |
| Day High | 0.87 |
| Day Low | 0.79 |
| 52-Week High | 3.92 |
| 52-Week Low | 0.66 |
| Volume | 236,209 |
| Average Volume | 1.06M |
| Market Cap | 76.99M |
| PE | -0.5 |
| EPS | -1.65 |
| Moving Average 50 Days | 0.92 |
| Moving Average 200 Days | 1.66 |
| Change | 0.04 |
If you invested $1000 in Caribou Biosciences, Inc. (CRBU) since IPO date, it would be worth $50.72 as of May 09, 2025 at a share price of $0.828. Whereas If you bought $1000 worth of Caribou Biosciences, Inc. (CRBU) shares 3 years ago, it would be worth $124.11 as of May 09, 2025 at a share price of $0.828.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
GlobeNewswire Inc.
May 06, 2025 8:00 PM GMT
BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive off
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
GlobeNewswire Inc.
Apr 24, 2025 8:15 PM GMT
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-0
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
GlobeNewswire Inc.
Jan 13, 2025 12:05 AM GMT
-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data ex